Company intelligence / Profile preview

ALS Investment Fund

Ownership: Private
Employees: ~7
Development stage: Other

Overview

ALS Investment Fund is a specialized venture capital firm investing globally—primarily in Europe and the US—in biotech companies developing therapeutics for neurodegenerative diseases, especially ALS. It has supported several successful exits including Amylyx Pharmaceuticals. The team brings deep scientific expertise and leverages a strong advisory network from leading academic institutions.

Therapeutic areas: Neurology
Modalities: Small moleculeBiologicAntibody
Industry: Investors

Partnerships

Life Sciences PartnersUMASS (academic collaboration)MGH/Harvard (academic collaboration)UMC Utrecht (academic collaboration)

Beyond the preview

Go deeper on ALS Investment Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALS Investment Fund.

Explore the full profile